Clearside Biomedical Filed for Chapter 11

0
29

Advisors and Court Oversight

Clearside has tapped industry heavyweights to steer its restructuring:

  • Cooley LLP and Richards, Layton & Finger PA as bankruptcy counsel

  • Berkeley Research Group LLC as financial restructuring adviser

The case was assigned to U.S. Bankruptcy Judge Thomas M. Horan, who will oversee the company’s efforts to stabilize operations, market its assets, and potentially secure a buyer capable of carrying the technology forward.

A Sale That Could Define the Company’s Future

While Clearside enters Chapter 11 under pressure, the company’s leadership maintains that its platform—built on years of research—may still find a new life in the hands of a strategic acquirer. For now, the biotech firm’s fate hinges on a bankruptcy-court auction where its vision for the future will be measured against the market’s appetite for cutting-edge ophthalmic technology.

Signup for the USA Herald exclusive Newsletter